OBSERVATIONAL STUDY OF VERICIGUAT AND GDMT IN STAGE C HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION

This observational cohort study investigates the effectiveness of vericiguat in stage C heart failure patients with reduced ejection fraction (EF) who are not stabilized with guidelines directed medical therapy (GDMT). The study includes worsening heart failure patients with reduced EF, following AHA 2022 guidelines, with exclusion criteria covering severe renal or hepatic dysfunction, pregnancy, breastfeeding, and anemia. The control group comprises AHA stage C heart failure patients on GDMT. Endpoints include mortality, progression to advanced heart failure (AHA stage D), willingness to continue vericiguat, and study participation. The hypothesis tests whether vericiguat reduces HF stage C admissions and all-cause mortality over 12 months and increases EF compared to GDMT. The observation period spans six months with follow-up visits at one, three, and six months. Investigational assessments include CBC, 2D ECHO, and renal and liver function tests. This study aims to provide insights into the efficacy of vericiguat in stage C heart failure management.